Search Results Search Sort by RelevanceMost Recent State of the Art and Science Jan 2021 “Prevention” and Human Gene Editing Governance Eric T. Juengst, PhD The Holocaust and the racial hygiene doctrine that helped rationalize it still overshadow contemporary debates about using gene editing for disease prevention. AMA J Ethics. 2021;23(1):E49-54. doi: 10.1001/amajethics.2021.49. State of the Art and Science Nov 2017 How Should Organizations Promote Equitable Distribution of Benefits from Technological Innovation in Health Care? Satish Nambisan, PhD and Priya Nambisan, PhD Fair distribution demands new strategies for engaging patients in co-creation. AMA J Ethics. 2017;19(11):1106-1115. doi: 10.1001/journalofethics.2017.19.11.stas1-1711. State of the Art and Science Nov 2017 Why Aren’t Our Digital Solutions Working for Everyone? Brian Van Winkle, MBA, Neil Carpenter, MBA, and Mauro Moscucci, MD, MBA To fairly distribute the benefits of digital technologies, clinicians will need to be incentivized to adopt technologies that target the underserved. AMA J Ethics. 2017;19(11):1116-1124. doi: 10.1001/journalofethics.2017.19.11.stas2-1711. History of Medicine Nov 2017 How Co-Creation Helped Address Hierarchy, Overwhelmed Patients, and Conflicts of Interest in Health Care Quality and Safety Sigal Israilov and Hyung J. Cho, MD Co-creative health systems planning requires engaging patients and learning from peers. AMA J Ethics. 2017;19(11):1139-1145. doi: 10.1001/journalofethics.2017.19.11.mhst1-1711. Policy Forum Mar 2016 Shedding Privacy Along with our Genetic Material: What Constitutes Adequate Legal Protection against Surreptitious Genetic Testing? Nicolle K. Strand, JD, MBioethics Law doesn’t always adequately address unauthorized uses of individuals’ DNA. Ethics can help establish legal privacy protections that work. AMA J Ethics. 2016;18(3):264-271. doi: 10.1001/journalofethics.2016.18.3.pfor2-1603. AMA Code Says Nov 2020 AMA Code of Medical Ethics’ Opinions Related to Risk Management Ethics Scott J. Schweikart, JD, MBE and Deborah M. Eng, MS, MA Ethical dimensions of risk management are illuminated in AMA Code content on discharge planning. AMA J Ethics. 2020;22(11):E940-944. doi: 10.1001/amajethics.2020.940. Health Law Nov 2020 How Hospital Leaders and Risk Managers Can Nurture Ethics-Driven Lawyering Norine A. McGrath, MD, Evan G. DeRenzo, PhD, John K. Kilcullen, MD, JD, MPH, and Jack Schwartz, JD Hospital lawyers’ practices shape risk management operations, influence clinicians’ morale, and affect patient care. AMA J Ethics. 2020;22(11):E933-939. doi: 10.1001/amajethics.2020.933. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Medicine and Society Oct 2019 How Should Decision Aids Be Used During Counseling to Help Patients Who Are “Genetically at Risk”? Natalie Evans, PhD, Suzanne Metselaar, PhD, Carla van El, PhD, Nina Hallowell, DPhil, MA, and Guy Widdershoven, PhD Prognostic uncertainty about risk creates demand for ongoing communication and facilitated reflection about goals and values. AMA J Ethics. 2019;21(10):E865-872. doi: 10.1001/amajethics.2019.865. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page Next › Last page Last »
State of the Art and Science Jan 2021 “Prevention” and Human Gene Editing Governance Eric T. Juengst, PhD The Holocaust and the racial hygiene doctrine that helped rationalize it still overshadow contemporary debates about using gene editing for disease prevention. AMA J Ethics. 2021;23(1):E49-54. doi: 10.1001/amajethics.2021.49.
State of the Art and Science Nov 2017 How Should Organizations Promote Equitable Distribution of Benefits from Technological Innovation in Health Care? Satish Nambisan, PhD and Priya Nambisan, PhD Fair distribution demands new strategies for engaging patients in co-creation. AMA J Ethics. 2017;19(11):1106-1115. doi: 10.1001/journalofethics.2017.19.11.stas1-1711.
State of the Art and Science Nov 2017 Why Aren’t Our Digital Solutions Working for Everyone? Brian Van Winkle, MBA, Neil Carpenter, MBA, and Mauro Moscucci, MD, MBA To fairly distribute the benefits of digital technologies, clinicians will need to be incentivized to adopt technologies that target the underserved. AMA J Ethics. 2017;19(11):1116-1124. doi: 10.1001/journalofethics.2017.19.11.stas2-1711.
History of Medicine Nov 2017 How Co-Creation Helped Address Hierarchy, Overwhelmed Patients, and Conflicts of Interest in Health Care Quality and Safety Sigal Israilov and Hyung J. Cho, MD Co-creative health systems planning requires engaging patients and learning from peers. AMA J Ethics. 2017;19(11):1139-1145. doi: 10.1001/journalofethics.2017.19.11.mhst1-1711.
Policy Forum Mar 2016 Shedding Privacy Along with our Genetic Material: What Constitutes Adequate Legal Protection against Surreptitious Genetic Testing? Nicolle K. Strand, JD, MBioethics Law doesn’t always adequately address unauthorized uses of individuals’ DNA. Ethics can help establish legal privacy protections that work. AMA J Ethics. 2016;18(3):264-271. doi: 10.1001/journalofethics.2016.18.3.pfor2-1603.
AMA Code Says Nov 2020 AMA Code of Medical Ethics’ Opinions Related to Risk Management Ethics Scott J. Schweikart, JD, MBE and Deborah M. Eng, MS, MA Ethical dimensions of risk management are illuminated in AMA Code content on discharge planning. AMA J Ethics. 2020;22(11):E940-944. doi: 10.1001/amajethics.2020.940.
Health Law Nov 2020 How Hospital Leaders and Risk Managers Can Nurture Ethics-Driven Lawyering Norine A. McGrath, MD, Evan G. DeRenzo, PhD, John K. Kilcullen, MD, JD, MPH, and Jack Schwartz, JD Hospital lawyers’ practices shape risk management operations, influence clinicians’ morale, and affect patient care. AMA J Ethics. 2020;22(11):E933-939. doi: 10.1001/amajethics.2020.933.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Medicine and Society Oct 2019 How Should Decision Aids Be Used During Counseling to Help Patients Who Are “Genetically at Risk”? Natalie Evans, PhD, Suzanne Metselaar, PhD, Carla van El, PhD, Nina Hallowell, DPhil, MA, and Guy Widdershoven, PhD Prognostic uncertainty about risk creates demand for ongoing communication and facilitated reflection about goals and values. AMA J Ethics. 2019;21(10):E865-872. doi: 10.1001/amajethics.2019.865.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.